These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 7769843

  • 1. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S, Turner A, Nelms P, Yanovich S.
    Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
    [Abstract] [Full Text] [Related]

  • 2. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 3. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM, Rustum YM.
    Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [Abstract] [Full Text] [Related]

  • 4. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

  • 5. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
    Kong XB, Tong WP, Chou TC.
    Mol Pharmacol; 1991 Feb 01; 39(2):250-7. PubMed ID: 1705001
    [Abstract] [Full Text] [Related]

  • 6. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
    Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T.
    Int J Oncol; 2011 Apr 01; 38(4):911-9. PubMed ID: 21290089
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
    Grant S, Jarvis WD, Swerdlow PS, Turner AJ, Traylor RS, Wallace HJ, Lin PS, Pettit GR, Gewirtz DA.
    Cancer Res; 1992 Nov 15; 52(22):6270-8. PubMed ID: 1423273
    [Abstract] [Full Text] [Related]

  • 8. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR, Ford J, Dawson VM, Piall E, Aherne GW.
    Cancer Res; 1989 Jun 01; 49(11):3015-9. PubMed ID: 2720661
    [Abstract] [Full Text] [Related]

  • 9. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1780-6. PubMed ID: 19428333
    [Abstract] [Full Text] [Related]

  • 10. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD.
    Oncol Res; 1994 Jun 15; 6(2):87-99. PubMed ID: 7949469
    [Abstract] [Full Text] [Related]

  • 11. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV, Avramis VI.
    Cancer Chemother Pharmacol; 1995 Jun 15; 35(3):191-9. PubMed ID: 7805176
    [Abstract] [Full Text] [Related]

  • 12. Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity.
    Honma Y, Onozuka Y, Okabe-Kado J, Kasukabe T, Hozumi M.
    Cancer Res; 1991 Sep 01; 51(17):4535-8. PubMed ID: 1873797
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P, Lien EJ, Avramis VI.
    Anticancer Res; 1999 Sep 01; 19(3A):1625-33. PubMed ID: 10470093
    [Abstract] [Full Text] [Related]

  • 14. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo.
    Chiba P, Tihan T, Szekeres T, Salamon J, Kraupp M, Eher R, Köller U, Knapp W.
    Leukemia; 1990 Nov 01; 4(11):761-5. PubMed ID: 2232889
    [Abstract] [Full Text] [Related]

  • 15. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Cancer Res; 1982 Jul 01; 42(7):2846-51. PubMed ID: 7083175
    [Abstract] [Full Text] [Related]

  • 16. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
    Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.
    Biochem Pharmacol; 2004 Feb 01; 67(3):503-11. PubMed ID: 15037202
    [Abstract] [Full Text] [Related]

  • 17. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
    Grant S, Freemerman AJ, Birrer MJ, Martin HA, Turner AJ, Szabo E, Chelliah J, Jarvis WD.
    Cell Growth Differ; 1996 May 01; 7(5):603-13. PubMed ID: 8732670
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS.
    Cancer Chemother Pharmacol; 1989 May 01; 24(4):203-10. PubMed ID: 2473850
    [Abstract] [Full Text] [Related]

  • 19. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
    Kanno S, Hiura T, Ohtake T, Koiwai K, Suzuki H, Ujibe M, Ishikawa M.
    Clin Chim Acta; 2007 Feb 01; 377(1-2):144-9. PubMed ID: 17097625
    [Abstract] [Full Text] [Related]

  • 20. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S, Bhalla K, McCrady C.
    Leuk Res; 1991 Feb 01; 15(4):205-13. PubMed ID: 2030601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.